Tirzepatide: What the Research Actually Shows

What It Is

A Dual GIP/GLP-1 Receptor Agonist, One Molecule Acting on Two Incretin Systems

Tirzepatide is a synthetic 39-amino-acid peptide engineered to activate both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 receptor, the two major incretin hormone systems the gut uses to regulate insulin secretion, appetite, and gastric emptying after eating. Its designers built in two non-standard amino acids for enzymatic stability and a C20 fatty-diacid chain, attached through a linker, for reversible albumin binding, the same general strategy used in semaglutide, extending its half-life to roughly five days and enabling once-weekly dosing. At the receptor level, tirzepatide binds the GIP receptor with potency comparable to native GIP, while its GLP-1 receptor activity is intentionally more moderate than a selective GLP-1 drug like semaglutide, a deliberate design choice its discovery paper describes as aiming for balanced dual-incretin signaling rather than maximizing GLP-1 potency alone. It is FDA-approved under different brand names for different indications: Mounjaro for type 2 diabetes, Zepbound for chronic weight management.

The Evidence

The Largest Weight-Loss Effect on This Site, and a More Nuanced Safety Picture Than It First Appears

Discovery and Mechanism: Engineering a Dual-Incretin Receptor Agonist

Coskun T, Sloop KW, Loghin C, et al. "LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept." Molecular Metabolism. 2018;18:3-14. doi: 10.1016/j.molmet.2018.09.009. PMID: 30473097. This discovery paper documents tirzepatide's engineering: a 39-amino-acid peptide (molecular weight 4,810.52 Da) with two non-standard amino acids for stability against enzymatic degradation and a C20 fatty-diacid moiety, linked to a lysine residue, enabling albumin binding and a roughly five-day half-life. Receptor-binding data show high-potency GIP receptor activity (comparable to native GIP) alongside deliberately more moderate GLP-1 receptor activity, roughly 13-fold weaker than native GLP-1 and less potent than the selective GLP-1 drug semaglutide, a balance the authors describe as intentional rather than a limitation.

Medicinal Chemistry / Receptor Pharmacology Study · Endpoint: Dual-Receptor Binding, Potency, and Half-Life, Mechanistic and Engineering Basis, Not a Clinical Outcome

Weight Loss: The SURMOUNT-1 Randomized Controlled Trial

Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022. doi: 10.1056/NEJMoa2206038. PMID: 35658024. This randomized, double-blind, placebo-controlled trial enrolled 2,539 adults with obesity or overweight (without diabetes) across three tirzepatide doses (5 mg, 10 mg, 15 mg) versus placebo, over 72 weeks. Mean body weight change was -15.0%, -19.5%, and -20.9% across the three ascending doses, versus -3.1% with placebo (p<0.001 for all comparisons). The most commonly reported adverse events were gastrointestinal, mild to moderate, and concentrated in the dose-escalation phase.

Human RCT (n=2,539), Randomized, Double-Blind, Dose-Ranging · Endpoint: Percent Body Weight Change at 72 Weeks, Large-Scale, Placebo-Controlled

Tirzepatide vs. Semaglutide, Directly: The SURMOUNT-5 Head-to-Head Trial

Aronne LJ, Horn DB, le Roux CW, et al. "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity." New England Journal of Medicine. 2025;393(1):26-36. doi: 10.1056/NEJMoa2416394. PMID: 40353578. This is a genuinely rare and valuable kind of trial in this space: a direct, randomized, head-to-head comparison of two active drugs rather than each being tested separately against placebo. In 751 adults with obesity (no diabetes) across 32 U.S. sites, tirzepatide produced significantly greater weight loss than semaglutide at 72 weeks, -20.2% versus -13.7% (least-squares mean, p<0.001), and greater waist circumference reduction (-18.4 cm versus -13.0 cm, p<0.001). Weight loss was about 6% lower in men than women in both groups, a real, stated sex difference worth noting rather than glossing over.

Human RCT, Head-to-Head Active-Comparator Design (n=751) · Endpoint: Percent Body Weight Change at 72 Weeks, Direct Randomized Comparison, Not Cross-Trial Extrapolation

What the Weight Loss Is Made Of: A Full Peer-Reviewed Body Composition Study

Look M, Dunn JP, Kushner RF, et al. "Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight." Diabetes, Obesity and Metabolism. 2025;27(5):2720-2729. doi: 10.1111/dom.16275. PMID: 39996356. In this DXA sub-study of 160 SURMOUNT-1 participants (124 tirzepatide, 36 placebo), tirzepatide produced a 21.3% total body weight reduction versus 5.3% with placebo, made up of a 33.9% reduction in fat mass (versus 8.2% with placebo) and a 40.1% reduction in visceral fat mass (versus 7.3% with placebo), alongside a 10.9% reduction in lean mass (versus 2.6% with placebo). Critically, when expressed as a proportion of total weight lost, the composition was nearly identical between groups: about 74% fat mass and 26% lean mass with tirzepatide, versus about 75% fat mass and 25% lean mass with placebo. This is a full peer-reviewed publication, not a conference abstract, and its central finding, that the fat-to-lean ratio of weight lost wasn't meaningfully different from diet-driven weight loss, is more precise than the common claim that GLP-1-class drugs disproportionately burn muscle.

Human RCT Sub-Study, DXA Body Composition (n=160), Full Peer-Reviewed Publication · Endpoint: Fat Mass and Lean Mass Change at 72 Weeks, Proportional Composition of Weight Lost

Cardiovascular Outcomes in Type 2 Diabetes: SURPASS-CVOT

Nicholls SJ, Pavo I, Bhatt DL, et al. "Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes." New England Journal of Medicine. 2025;393(24):2409-2420. doi: 10.1056/NEJMoa2505928. This large trial enrolled 13,299 patients with type 2 diabetes and established atherosclerotic cardiovascular disease, and compared tirzepatide against dulaglutide, an active GLP-1 comparator already shown to reduce cardiovascular events, rather than against placebo, over a median follow-up of 4 years. The primary composite outcome (cardiovascular death, heart attack, or stroke) occurred in 12.2% of the tirzepatide group versus 13.1% with dulaglutide, meeting the trial's prespecified noninferiority threshold (p=0.003) but not reaching statistical superiority (p=0.09). This is meaningfully different evidence than semaglutide's SELECT trial: SURPASS-CVOT shows tirzepatide performs at least as well as an already-proven active comparator in diabetes, not that it beats placebo on hard cardiovascular outcomes in a population without diabetes, and the two shouldn't be treated as equivalent evidence.

Human RCT (n=13,299), Randomized, Active-Comparator (Not Placebo-Controlled), Type 2 Diabetes Population · Endpoint: Composite Cardiovascular Events Over 4 Years, Noninferiority Met, Superiority Not Demonstrated

Maintaining the Loss, and What Happens After Stopping: SURMOUNT-4

Aronne LJ, Sattar N, Horn DB, et al. "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial." JAMA. 2024;331(1):38-48. doi: 10.1001/jama.2023.24945. This is the trial that isolates the question most patients ask before starting. All 783 participants received open-label tirzepatide at the maximum tolerated dose (10 or 15 mg) for 36 weeks and lost an average of 20.9% of body weight. The 670 who completed that lead-in were then randomized to continue tirzepatide or switch to placebo for a further 52 weeks, with diet and physical activity support maintained in both arms. From week 36 to week 88, the group that continued lost an additional 5.5%, while the group switched to placebo regained 14.0%, a difference of 19.4 percentage points. The maintenance endpoint states it most plainly: 89.5% of those who stayed on treatment held at least 80% of the weight they had lost, compared with 16.6% of those switched to placebo. Total reduction from week 0 to week 88 was 25.3% with continued tirzepatide versus 9.9% with placebo. Two conclusions follow. Withdrawal produces substantial regain, which is a finding about the physiology of treated obesity rather than about patient adherence. And that regain is partial rather than complete: the placebo arm remained nearly 10% below its starting weight a full year after the drug was withdrawn.

Human RCT (n=670 Randomized), 36-Week Open-Label Lead-In Followed by 52-Week Double-Blind, Placebo-Controlled Randomized Withdrawal · Endpoint: Percent Weight Change From Randomization to Week 88, Plus Maintenance of At Least 80% of Lead-In Loss

Sources

References